Revolution Medicines, Inc. Common Stock (RVMD) Stock
Key stats
- Market cap
- $39.08B
- Price / Earnings ratio
- -22.3x
- EPS (TTM)
- -$9.14
- Volume
- Loading
- 52-week high
- $224.31
- 52-week low
- $62.29
Source: third-party data provider, as of November 13, 2026
Compare with RVMD
Recent news

Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
RVMD

Could Revolution Medicines Be a Millionaire-Maker Stock?
Could Revolution Medicines Be a Millionaire-Maker Stock?
RVMD

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
RVMD

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
RVMD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.67
- MACD 12/26/9
- -1.52
- EMA 9 of MACD
- -1.75
- MACD histogram
- 0.24
- SMA 50
- $195.89
- Price below SMA 50
- EMA 50
- $192.94
- Price below EMA 50
- SMA 200
- $159.11
- Price above SMA 200
- EMA 200
- $156.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
RVMD

Could Revolution Medicines Be a Millionaire-Maker Stock?
Could Revolution Medicines Be a Millionaire-Maker Stock?
RVMD

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
RVMD

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
RVMD

EMA recommends approval of Revolution's pancreatic cancer drug
EMA recommends approval of Revolution's pancreatic cancer drug
RVMD

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
RVMD

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
RVMD

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
RVMD

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
RVMD

New drug shows promise for lung cancer
New drug shows promise for lung cancer
RVMD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Revolution Medicines, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 1962 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | — |
| Mr. Jack Anders | Chief Financial Officer | 1977 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 1975 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 1961 |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | — |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 43.67
- MACD 12/26/9
- -1.52
- EMA 9 of MACD
- -1.75
- MACD histogram
- 0.24
- SMA 50
- $195.89
- Price below SMA 50
- EMA 50
- $192.94
- Price below EMA 50
- SMA 200
- $159.11
- Price above SMA 200
- EMA 200
- $156.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $179.00
- Average
- $270.65
- High
- $350.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.0 | -5.7 | ||||||||||
| 2022 | -17.7 | -15.3 | +37.4 | -22.1 | -19.7 | +18.0 | +8.1 | +5.1 | -8.7 | +3.7 | +13.5 | +0.7 |
| 2023 | +16.5 | -1.2 | -18.3 | +10.4 | +4.5 | +6.2 | -2.2 | +7.8 | -21.0 | -24.3 | +14.6 | +17.1 |
| 2024 | -1.7 | +4.3 | +8.2 | +17.7 | -1.3 | -3.4 | +17.6 | -5.8 | +9.1 | +18.4 | +5.0 | -15.6 |
| 2025 | -2.4 | -3.3 | -7.8 | +20.1 | -3.1 | -9.5 | +1.0 | +3.7 | +18.1 | +28.3 | +31.1 | +5.1 |
| 2026 | +22.7 | +5.0 | -4.3 | +46.1 | +12.9 | +14.4 | +0.0 | +12.7 | -2.2 | -7.1 | -4.0 |



